Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1647 1674
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18059315 | ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18021641 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MEMBRANOUS NEPHROPATHY | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18224463 | FORMULATED RECEPTOR POLYPEPTIDES AND RELATED METHODS | Non-Final OA | AMGEN INC. |
| 18481107 | SYNTHEKINE COMPOSITIONS AND METHODS OF USE | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17749977 | SYNERGISTIC IMMUNOSTIMULATION THROUGH THE DUAL ACTIVATION OF TLR3/9 WITH SPHERICAL NUCLEIC ACIDS | Final Rejection | NORTHWESTERN UNIVERSITY |
| 18236453 | DIAGNOSTICS OF GINGIVITIS | Final Rejection | KONINKLIJKE PHILIPS N.V. |
| 17732926 | BLOOD-BASED BIOMARKERS AND USE THEREOF FOR TREATING CANCER | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 16970688 | Novel IL-4-/IL-13-derived peptide compounds for the treatment or prevention of neurodegenerative or neuroinflammatory diseases | Non-Final OA | Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
| 18353133 | ANTI-IL-36R ANTIBODY FORMULATIONS | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17041006 | METHODS OF TREATING MINIMAL RESIDUAL CANCER | Final Rejection | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| 18015169 | BIOFLUID-BASED PROTEIN AND MIRNA BIOMARKERS FOR NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 17997616 | COMPOSITIONS AND METHODS FOR PREVENTING, DETECTING, AND TREATING INFLAMMATORY BOWEL DISEASE | Non-Final OA | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO |
| 18344502 | ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS | Final Rejection | QUEEN MARY UNIVERSITY OF LONDON |
| 17768757 | Immunogenic Compounds For Treatment Of Adrenal Cancer | Final Rejection | ENTEROME S.A. |
| 17928988 | S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME | Non-Final OA | THE DOSHISHA |
| 18006668 | DRUG-SPECIFIC PHARMACOKINETIC ASSAY FOR IL-15 SUPERAGONIST | Non-Final OA | NANTCELL, INC. |
| 17986255 | METHOD FOR PREDICTING THE RISK OF INCIDENCE OF CHRONIC KIDNEY DISEASE | Non-Final OA | Sphingotec GmbH |
| 17766823 | STABLE FORMULATION OF INTEGRIN ANTIBODY | Final Rejection | DR. REDDY'S LABORATORIES LIMITED |
| 17922976 | PHARMACEUTICAL COMPOSITIONS COMPRISING ADALIMUMAB | Non-Final OA | SHILPA BIOLOGICALS PRIVATE LIMITED |
| 17997832 | Treatment of Hyperuricemia | Non-Final OA | Frederiksberg Hospital |
| 17044729 | MEDICAL INFUSION PUMP SYSTEM FOR THE DELIVERY OF AN INSULIN COMPOUND | Final Rejection | ARECOR LIMITED |
| 17905480 | COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF DISEASES | Non-Final OA | ILC THERAPEUTICS LIMITED |
| 17759559 | HUMAN ANTI-INFLAMMATORY PEPTIDES FOR THE INHALATORY TREATMENT OF INFLAMMATORY PULMONARY ISSUES | Non-Final OA | ADVITA LIFESCIENCE GMBH |
| 17777385 | METHOD TO INCREASE ANTIBODY YIELD DURING ION EXCHANGE CHROMATOGRAPHY | Non-Final OA | MORPHOSYS GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy